EHC/eu-patient.eu
Oct 16, 2026, 12:30
Why VWF Therapies Belong on the EU Critical Medicines List – EHC
EHC – European Haemophilia Consortium shared a post on LinkedIn:
“For many people with von Willebrand Disease (VWD), von Willebrand Factor (VWF) replacement is the only effective treatment. If supply runs short, there is no fallback.
That’s why the EHC is asking the European Medicines Agency and EU Member States to add VWF therapies to the EU List of Critical Medicines, so their supply gets closer monitoring and stronger safeguards. 🇪🇺
Swipe through for the key questions, and read the full campaign.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH
-
Oct 16, 2026, 10:07Habib Bennaceur: Building a Stronger Care Pathway for Sickle Cell Disease in India
-
Oct 16, 2026, 09:59Tareq Abadl: A Simple Guide to Blood Collection Tubes
-
Oct 16, 2026, 09:50Mona Alfaraj: Distinguishing HCL from SMZL in Bone Marrow
-
Oct 16, 2026, 09:44New International Consensus on Covert Brain Infarction – International Journal of Stroke
-
Oct 16, 2026, 06:17Neha Rastogi Panda: Precision Diagnosis and Organ Preservation in Splenic Abscess
-
Oct 16, 2026, 05:53Alejandro González Veliz: Looking Beyond Coronary Anatomy to Understand Ischemia
-
Oct 16, 2026, 04:16Asmaa M. Gouda: Advancing Blood Bank Leadership at Alexandria University Hospitals